IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
This study has been completed.
Sponsor:
Boehringer Ingelheim
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01325428
First received: March 28, 2011
Last updated: June 17, 2016
Last verified: June 2016
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, locally advanced or metastatic inflammatory breast cancer. The study will include patients who have and have not failed prior trastuzumab treatment.
| Condition | Intervention | Phase |
|---|---|---|
| Breast Neoplasms | Drug: Afatinib once daily (OD) Drug: Vinorelbine Weekly | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
breast cancer
MedlinePlus related topics:
Breast Cancer
U.S. FDA Resources
Further study details as provided by Boehringer Ingelheim:
Primary Outcome Measures:
- Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). [ Time Frame: This endpoint was assessed between the from first administration of trial medication in Part A and the earliest of PD, death or start of next treatment (either Part B combination therapy or new anti-cancer therapy) up to 929 days. ]Tumour response was assessed separately for Part A and Part B according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The primary endpoint of this study was confirmed clinical benefit, as assessed by Stable Disease (SD) for at least 6 months (defined as >182 days), Partial Response (PR), or Complete Response (CR) according to RECIST version 1.1 (only confirmed responses were considered).
- Part B: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). [ Time Frame: This endpoint was recorded from first administration of trial medication in Part B until the earliest of PD, death or start of new anti-cancer therapy up to 929 days. ]Tumour response was assessed separately for Part B according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The primary endpoint of this study was confirmed clinical benefit, as assessed by Stable Disease (SD) for at least 6 months (defined as >182 days), Partial Response (PR), or Complete Response (CR) according to RECIST version 1.1 (only confirmed responses were considered).
Secondary Outcome Measures:
- Part A: Confirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1). [ Time Frame: This endpoint was recorded from first administration of trial medication until the earliest of disease progression, death or start of next treatment (either Part B combination therapy or new anti-cancer therapy) up to 929 days. ]Objective response was defined on a patient level as a best response of CR or PR.
- Part B: Confirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1). [ Time Frame: This endpoint was recorded from first administration of trial medication in Part B and until the earliest of disease progression, death or start of new anti-cancer therapy up to 929 days. ]Objective response was defined on a patient level as a best response of CR or PR.
- Part A: Unconfirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1). [ Time Frame: This endpoint was recorded from first administration of trial medication until the earliest of PD, death or start of next treatment (either Part B combination therapy or new anti-cancer therapy) up to 929 days. ]Objective response was defined on a patient level as a best response of CR or PR.
- Part B: Unconfirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1 ). [ Time Frame: This endpoint was recorded from first administration of trial medication in Part B and until the earliest of PD, death or start of new anti-cancer therapy up to 929 days. ]Objective response was defined on a patient level as a best response of CR or PR.
- Part A: Duration of Unconfirmed Objective Response. [ Time Frame: From first drug administration until end of Part A, up to 929 days. ]Objective Response (OR) was defined on a patient level as a best response of Complete Response (CR) or Partial Response (PR). Duration of objective response was measured from the time of first unconfirmed objective response to the time of progression or death (or date of censoring for Progression Free Survival (PFS)).
- Part B: Duration of Unconfirmed Objective Response. [ Time Frame: From first drug administration until end of Part B, up to 929 days. ]Objective response was defined on a patient level as a best response of CR or PR. Duration of objective response was measured from the time of first unconfirmed objective response to the time of progression or death (or date of censoring for PFS).
- Part A: Progression Free Survival. [ Time Frame: From first drug administration until end of Part A, up to 713 days. ]PD was evaluated according to the RECIST version 1.1. For patients with a known date of progression (or death), PFS was the earlier of date of progression or death - date of first administration + 1. The date of progression and date of first administration referred to the respective part of the study A.
- Part B: Progression Free Survival. [ Time Frame: From first drug administration until end of Part B, up to 230 days. ]PD was evaluated according to the RECIST version 1.1. For patients with a known date of progression (or death), PFS was the earlier of date of progression or death - date of first administration + 1. The date of progression and date of first administration referred to the respective part of the study B.
- Progression Free Survival Over the Whole Sudy. [ Time Frame: From first drug administration until end of study, up to 700 days. ]PD was evaluated according to the RECIST version 1.1. Number of days from the start of monotherapy to the date of second PD.
| Enrollment: | 26 |
| Study Start Date: | August 2011 |
| Study Completion Date: | November 2014 |
| Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Afatinib once daily (OD)
Patients receive afatinib monotherapy once daily until progression of their disease
|
Drug: Afatinib once daily (OD)
Patient to receive afatinib monotherapy until progression of their disease
Drug: Vinorelbine Weekly
Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer
- Locally advanced or metastatic disease
- Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1)
- For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment
- Investigator-confirmed diagnosis of Inflammatory Breast Cancer
- Must have biopsiable disease
Exclusion criteria:
- Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population)
- Must not have received prior vinorelbine treatment
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325428
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325428
Locations
| United States, California | |
| 1200.89.10001 Boehringer Ingelheim Investigational Site | |
| Los Angeles, California, United States | |
| United States, North Carolina | |
| 1200.89.10005 Boehringer Ingelheim Investigational Site | |
| Durham, North Carolina, United States | |
| Australia, Victoria | |
| 1200.89.61002 Boehringer Ingelheim Investigational Site | |
| East Bentleigh, Victoria, Australia | |
| Australia, Western Australia | |
| 1200.89.61003 Boehringer Ingelheim Investigational Site | |
| Perth, Western Australia, Australia | |
| Hong Kong | |
| 1200.89.85201 Boehringer Ingelheim Investigational Site | |
| Hong Kong, Hong Kong | |
| Korea, Republic of | |
| 1200.89.82001 Boehringer Ingelheim Investigational Site | |
| Seoul, Korea, Republic of | |
| 1200.89.82002 Boehringer Ingelheim Investigational Site | |
| Seoul, Korea, Republic of | |
| Thailand | |
| 1200.89.66002 Boehringer Ingelheim Investigational Site | |
| Bangkok, Thailand | |
| 1200.89.66004 Boehringer Ingelheim Investigational Site | |
| Bangkok, Thailand | |
| 1200.89.66003 Boehringer Ingelheim Investigational Site | |
| Chiangmai, Thailand | |
| 1200.89.66001 Boehringer Ingelheim Investigational Site | |
| Hat-Yai, Songkhla, Thailand | |
| Tunisia | |
| 1200.89.21601 Boehringer Ingelheim Investigational Site | |
| Ariana, Tunisia | |
| 1200.89.21602 Boehringer Ingelheim Investigational Site | |
| Sousse, Tunisia | |
| United Kingdom | |
| 1200.89.44002 Boehringer Ingelheim Investigational Site | |
| Bournemouth, United Kingdom | |
| 1200.89.44001 Boehringer Ingelheim Investigational Site | |
| London, United Kingdom | |
| 1200.89.44003 Boehringer Ingelheim Investigational Site | |
| London, United Kingdom | |
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT01325428 History of Changes |
| Other Study ID Numbers: |
1200.89 2010-024454-10 ( EudraCT Number: EudraCT ) |
| Study First Received: | March 28, 2011 |
| Results First Received: | November 17, 2015 |
| Last Updated: | June 17, 2016 |
Additional relevant MeSH terms:
|
Breast Neoplasms Inflammatory Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Vinorelbine |
Vinblastine Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on September 25, 2017